Name: Hemodynamic Flow Alteration Devices Market Size, Share, Industry, Forecast and outlook (2023-2030)
Brand: DataM Intelligence
SKU: MD4788
Price: 4350 USD
Availability: InStock

Hemodynamic Flow Alteration Devices Market Share, Size, Insights 2022

Hemodynamic Flow Alteration Devices Market Size, Share, Industry, Forecast and outlook (2023-2030)

<h2>Hemodynamic Flow Alteration Devices Market is Segmented By Type (Embolic protection devices, Chronic total occlusion devices), By End-User (Hospitals, Clinics, Ambulatory Care Center, Home Care Setting, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) &ndash; Share, Size, Outlook, and Opportunity Analysis, 2023-2030.</h2>

Hemodynamic Flow Alteration Devices Market is Expected to reach at a <a href="https://www.datamintelligence.com/download-sample/hemodynamic-flow-alteration-devices-market">CAGR of 8.7%</a> during the forecast period (2023-2030). Hemodynamic flow alteration devices are used in treating peripheral vascular diseases which are caused by the formation of atherosclerotic plaques in arteries, which are responsible for the circulation of blood in various organs, the head, and the limbs. The rising prevalence of cardiac disorders and <a href="https://www.datamintelligence.com/research-report/diabetes-therapeutics-market">diabetes</a>, rising demand for home-based and non-invasive monitoring systems, advances in technology, increasing funding from private players and government bodies, and an increase in the number of people suffering from hypertension are some of the factors driving the growth of the market.

<h3>Hemodynamic Flow Alteration Devices Market Statistics</h3>

<table border="1" cellpadding="1" cellspacing="1">
	<tbody>
		<tr>
			<td>
			Metrics
			</td>
			<td>
			Details
			</td>
		</tr>
		<tr>
			<td>
			Market&nbsp;CAGR
			</td>
			<td>
			8.7%
			</td>
		</tr>
		<tr>
			<td>
			Segments Covered
			</td>
			<td>
			By Type,&nbsp;By End-User,&nbsp;By Form,&nbsp;By Application,&nbsp;and By Region
			</td>
		</tr>
		<tr>
			<td>
			Report Insights Covered
			</td>
			<td>
			Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.
			</td>
		</tr>
		<tr>
			<td>
			Fastest Growing Region
			</td>
			<td>
			Asia Pacific
			</td>
		</tr>
		<tr>
			<td>
			Largest Market Share&nbsp;
			</td>
			<td>
			North America
			</td>
		</tr>
	</tbody>
</table>

Increasing R&amp;D investments in the pharmaceuticals and biotechnology industry will drive the market growth 

Neurosurgeons and other medical professionals are increasingly interested in therapeutic options that can effectively reduce the risk of fatality or severity of neurovascular diseases in patients. With an increasing number of patients suffering from neurovascular diseases (such as epilepsy, brain stroke, and cerebral aneurysm) and the severity of medical conditions (such as bleeding and local infections) in target patients, demand for effective neurovascular treatments is increasing across key markets such as the United States, Germany, Japan, China, and India. A cerebral aneurysm, for example, is a common neurovascular disorder all over the world. This condition is associated with a significant risk of bleeding or permanent neurological damage. In the United States, there will be 6.5 million brain aneurysm instances documented by 2020; additionally, 30,000 people will have a brain aneurysm rupture each year.

Demand for minimally invasive neurosurgery operations is on the rise. Minimally invasive medical procedures have several advantages over traditional surgical procedures, including a shorter hospital stay, faster patient recovery, increased procedural safety and efficacy, and lower costs. As a result, medical experts worldwide are becoming more accepting of endoscopic and other minimally invasive surgical methods. Geriatric patients are more vulnerable to neurovascular and neurological disorders. They choose treatment options that provide simple diagnosis, simple treatments, increased safety, the shortest possible hospital stay, improved efficacy, and acceptable costs.

Furthermore, aging rises the risk of thrombotic events such as pulmonary embolism, stroke, and epilepsy, all of which can necessitate neurosurgical surgery. Furthermore, arteriovenous malformations can cause hemorrhages and seizures, most common in those over the age of 40. (Source: Medscape). As a result, the growing elderly population and the need for minimally invasive procedures will likely provide considerable growth possibilities for both established and fledgling hemodynamic flow alteration devices companies.

Furthermore, patient awareness about coronary heart diseases and peripheral vascular disorders plays a vital role in market growth. Several educational, government and non-governmental organizations and key players have launched awareness programs to increase awareness about these diseases among patients, doctors, and healthcare providers. The impact of this factor currently influences the market growth in the emerging economies, as the adoption of advanced treatment devices is low in developing nations.

Various governments, particularly those in emerging economies, have boosted their spending on developing their healthcare infrastructure over the last decade. As a result, increased public and private investment in these regions&#39; health infrastructure will boost the adoption of hemodynamic flow alteration devices in developing countries. This contributes to the growth of the global hemodynamic flow alteration devices market.

Risk involved in invasive procedures is likely to hamper the market growth &nbsp;

Apart from the discomfort of invasive monitoring (particularly the insertion of the pulmonary artery catheter), there are several risks associated with this technique, including sepsis, bleeding, cardiac arrhythmias, decreased circulation to the distal limb, bleeding, nerve damage (during insertion), thrombosis, air embolism, and pulmonary capillary necrosis. These factors increase the likelihood of death during invasive hemodynamic procedures. As a result, invasive hemodynamic flow alteration devices is only recommended for a few indications where the risks outweigh the benefits of obtaining the necessary data during the procedure. In addition, invasive hemodynamic flow alteration devices are not recommended for elderly or frail patients. Furthermore, invasive hemodynamic monitoring is prohibitively expensive and necessitates the insertion of catheters into patients by skilled professionals. Although invasive hemodynamic monitoring gives accurate, comprehensive, and continuous data on a patient&#39;s hemodynamic state, the above hazards limit its usage. Price regulations, competitive pricing, coverage and payment policies, technical assessments, and comparative effectiveness of therapies are other factors reducing healthcare-related costs. The lengthy regulatory authentication/validation process for developing providers is expected to stifle the growth of hemodynamic flow alteration devices market.

<h3>Hemodynamic Flow Alteration Devices Market Segment Analysis</h3>

The embolic protection devices segment is expected to grow at the fastest CAGR during the forecast period (2021-2028) &nbsp;

The hemodynamic flow alteration devices market is divided into embolic protection devices and chronic total occlusion devices. The embolic protection devices segment accounted for most of the hemodynamic flow alteration devices market in 2019. This is due to the advantages of EPDs over CTO devices, such as the ability to capture embolic debris while maintaining continuous blood flow. To prevent distal embolization, embolic protection devices (EPD) trap blood and luminal debris within the saphenous vein graft (SVG) during stenting. These devices are classified into three types: distal occlusion devices, distal filters, and proximal occlusion devices. By capturing and removing debris that may become dislodged during surgical procedures such as SVG interventions, percutaneous coronary intervention, aortic valve stenosis, and so on, these devices provide the most proven strategy for reducing periprocedural myocardial infarction (MI) and major adverse cardiovascular events. EPDs are critical in reducing complications caused by blockages in small blood vessels caused by debris in the bloodstream. They are a component of the most dependable, evidence-based procedure for lowering periprocedural MI and other major cardiovascular events.

The launch of new products are also boosting this segment. For instance, in October 2020, Keystone Heart Ltd., a Venus Medtech Company, received the European CE mark for the TriGUARD 3 Cerebral Embolic Protection (CEP) Device. It is designed and innovated to reduce the risk of cerebral damage by deflecting embolic debris away from the brain. This is done from cerebral circulation during Transcatheter Aortic Valve Implantation (TAVI) and other surgical transcatheter heart procedures.

Furthermore, Contego Medical, LLC received CE Mark for the new product Vanguard IEPa in April 2017. It is a Peripheral Balloon Angioplasty System with Integrated Embolic Protection. Furthermore, the company intends to market the product to endovascular specialists who perform lower limb angioplasty procedures in Europe. The system represents the most recent advancement in Contego&#39;s Integrated Embolic Protection (IEP) technology, incorporating a peripheral angioplasty balloon and a distal embolic filter on the same catheter.

<h3>Hemodynamic Flow Alteration Devices Market Geographical Analysis</h3>

North America region holds the largest market share of global hemodynamic flow alteration devices market

North America is expected to dominate the market in the forecast period. The rising prevalence of cardiovascular and neurovascular diseases in the region is a major factor driving the growth of the embolic protection devices market in the coming years. Obesity prevalence, lifestyle patterns, and unhealthy dietary habits will all have a positive impact on regional market growth. The strong presence of major industry players in North America will fuel the growth of the hemodynamic flow alteration devices industry.

<h3>Hemodynamic Flow Alteration Devices Market Competitive Landscape</h3>

The hemodynamic flow alteration devices market is highly competitive with presence of local as well as global companies. &nbsp;Some of the key players which are contributing to the growth of the market include Abbott Laboratories, Medtronic, Boston Scientific, Cordis, Contego Medical, Claret Medical , BD, Biosensors International Group Ltd.

The market for hemodynamic monitoring is fiercely competitive, with several leading companies. Few big firms currently dominate the market in terms of market share. On the other hand, mid-size to smaller businesses are expanding their market presence by releasing new gadgets at lower rates, thanks to technical improvements and product innovations. For instance, in 2020, Cerenovus Stroke Solutions, a suite of three devices designed to assist physicians in clot removal procedures, was launched by Johnson &amp; Johnson. Cerenovus Large Bore Catheter, Cerebase DA Guide Sheath, and Embotrap III Revascularization Device are among the devices.

<h3>Hemodynamic Flow Alteration Devices Market&nbsp;COVID-19 Impact Analysis</h3>

COVID-19 pandemic has impacted on every aspect of the medical device industry, including the market for hemodynamic flow alteration devices. Even though emergency and outpatient services are available in cardiology departments, the number of patient visits to hospitals has decreased significantly in the last six months. Patient visits have been significantly reduced due to nationwide lockdowns and social distancing measures. This has resulted in even lower sales of hemodynamic flow alteration devices products.

&nbsp;Key Developments

<ul>
	<li>In 2019, In a feasibility study done in Europe, Innovative Cardiovascular Solutions revealed the first successful clinical use of its next-generation embolic protection device, Emblok, in patients undergoing transcatheter aortic valve implantation (TAVI).</li>
	<li>In 2018, Claret Medical, Inc., a major firm known for creating Sentinel, a Cerebral Embolic Protection System, has been acquired by Boston Scientific Corporation.</li>
</ul>

Abbott Laboratories

Overview: <a href="https://www.abbott.com/about-abbott/our-heritage.html">Abbott Laboratories</a> is a healthcare corporation and medical device based in Abbott Park, Illinois, United States. In 1888, Chicago physician Wallace Calvin Abbott created the company to develop well-known pharmaceuticals; now, it distributes medical devices, diagnostics, branded generic medicines, and nutritional supplements. In 2013, it separated its research-based pharmaceuticals business into AbbVie.

Product Portfolio:

Embolished NAV6TM:&nbsp; The Emboshield NAV6TM, Embolic Protection System, is indicated for use as a guidewire and embolic protection system to contain and remove embolic material (thrombus/debris) while performing angioplasty and stenting procedures in carotid arteries and atherectomy in lower extremity arteries, either alone or in conjunction with PTA and stenting. The artery diameter at the location of the Filtration Element should be between 2.5 and 7.0 mm.

<h3 style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px">Trending Topics</h3>

<a href="https://www.datamintelligence.com/research-report/hemodynamic-monitoring-systems-market">Hemodynamic Monitoring Systems</a>

<h2 style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px">Table of Contents</h2>

<ol>
	<li>
	Methodology and Scope

	<ol>
		<li>Research Methodology</li>
		<li>Research Objective and Scope of the Report</li>
	</ol>
	</li>
	<li>
	Market Definition and Overview
	</li>
	<li>
	Executive Summary

	<ol>
		<li>Market Snippet by Type</li>
		<li>Market snippet by End User</li>
		<li>Market Snippet by Region</li>
	</ol>
	</li>
	<li>
	Market Dynamics

	<ol>
		<li>Market Impacting Factors
		<ol>
			<li>Drivers
			<ol>
				<li>Increasing R&amp;D investments in the pharmaceuticals and biotechnology industry.</li>
				<li>Product approvals</li>
				<li>Increasing prevalence of diabetes</li>
			</ol>
			</li>
			<li>Restraints:
			<ol>
				<li>Product failure and recalls</li>
				<li>Postoperative complications</li>
			</ol>
			</li>
			<li>Opportunity</li>
			<li>Impact Analysis</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>
	Industry Analysis

	<ol>
		<li>Porter&#39;s Five Forces Analysis</li>
		<li>Supply Chain Analysis</li>
		<li>Pricing Analysis</li>
		<li>Regulatory Analysis</li>
		<li>Reimbursement Analysis</li>
	</ol>
	</li>
	<li>
	COVID-19 Analysis

	<ol>
		<li>Analysis of Covid-19 on the Market
		<ol>
			<li>Before COVID-19 Market Scenario</li>
			<li>Present COVID-19 Market Scenario</li>
			<li>After COVID-19 or Future Scenario</li>
		</ol>
		</li>
		<li>Pricing Dynamics Amid Covid-19</li>
		<li>Demand-Supply Spectrum</li>
		<li>Government Initiatives Related to the Market During Pandemic</li>
		<li>Manufacturers Strategic Initiatives</li>
		<li>Conclusion&nbsp;</li>
	</ol>
	</li>
	<li>
	By Type

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type Segment</li>
			<li>Market Attractiveness Index, By Type &nbsp;Segment</li>
		</ol>
		</li>
		<li>Embolic protection devices*
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028</li>
		</ol>
		</li>
		<li>Chronic total occlusion devices</li>
	</ol>
	</li>
	<li>
	By End User

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User</li>
			<li>Market Attractiveness Index, By End User Segment</li>
		</ol>
		</li>
		<li>Hospitals*
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028</li>
		</ol>
		</li>
		<li>Clinics</li>
		<li>Ambulatory Care Center</li>
		<li>Home Care Setting</li>
		<li>Others</li>
	</ol>
	</li>
	<li>
	By Region

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis, US$ Million, 2019-2029&nbsp;and Y-o-Y Growth Analysis (%), 2021-2029, By Region</li>
			<li>Market Attractiveness Index, By Region</li>
		</ol>
		</li>
		<li>North America
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type</li>
			<li>Market Size Analysis ,and Y-o-Y Growth Analysis (%), By End User</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>U.S.</li>
				<li>Canada</li>
				<li>Mexico</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Europe
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%),By End User</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>Germany</li>
				<li>U.K.</li>
				<li>France</li>
				<li>Italy</li>
				<li>Spain</li>
				<li>Rest of Europe</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>South America
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>Brazil</li>
				<li>Argentina</li>
				<li>Rest of South America</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Asia Pacific
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>China</li>
				<li>India</li>
				<li>Japan</li>
				<li>Australia</li>
				<li>Rest of Asia Pacific</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Middle East and Africa
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>
	Competitive Landscape

	<ol>
		<li>Key Developments and Strategies</li>
		<li>Company Share Analysis</li>
		<li>Product Benchmarking</li>
		<li>Key Companies to Watch</li>
	</ol>
	</li>
	<li>
	Company Profiles

	<ol>
		<li>Abbott Laboratories*
		<ol>
			<li>Company Overview</li>
			<li>Product Portfolio and Description</li>
			<li>Key Highlights</li>
			<li>Financial Overview</li>
		</ol>
		</li>
		<li>Medtronic</li>
		<li>Boston Scientific</li>
		<li>Cordis</li>
		<li>Contego Medical</li>
		<li>Claret Medical</li>
		<li>BD</li>
		<li>Biosensors International Group Ltd(*LIST NOT EXHAUSTIVE)</li>
	</ol>
	</li>
	<li>
	DataM Intelligence

	<ol>
		<li>Appendix</li>
		<li>About Us and Services</li>
		<li>Contact Us</li>
	</ol>
	</li>
</ol>

<h2 style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px">List of Tables &amp; Figures</h2>

List of Tables

Table 01 Global Hemodynamic Flow Alteration Devices Market Value, By Type, 2021, 2025 &amp; 2029 ($ Million)

Table 02 Global Hemodynamic Flow Alteration Devices Market Value, By End-User , 2021, 2025 &amp; 2029 ($ Million)

Table 03 Global Hemodynamic Flow Alteration Devices Market Value, By Region, 2021, 2025 &amp; 2029 ($ Million)

Table 04 Global Hemodynamic Flow Alteration Devices Market Value, By Type, 2021, 2025 &amp; 2029 ($ Million)

Table 05 Global Hemodynamic Flow Alteration Devices Market Value, By Type, 2020-2029 ($ Million)

Table 06 Global Hemodynamic Flow Alteration Devices Market Value, By End-User , 2021, 2025 &amp; 2029 ($ Million)

Table 07 Global Hemodynamic Flow Alteration Devices Market Value, By End-User , 2020-2029 ($ Million)

Table 08 Global Hemodynamic Flow Alteration Devices Market Value, By Region, 2021, 2025 &amp; 2029 ($ Million)

Table 09 Global Hemodynamic Flow Alteration Devices Market Value, By Region, 2020-2029 ($ Million)

Table 10 North America Hemodynamic Flow Alteration Devices Market Value, By Type, 2020-2029 ($ Million)

Table 11 North America Hemodynamic Flow Alteration Devices Market Value, By End-User , 2020-2029 ($ Million)

Table 12 North America Hemodynamic Flow Alteration Devices Market Value, By Country, 2020-2029 ($ Million)

Table 13 South America Hemodynamic Flow Alteration Devices Market Value, By Type, 2020-2029 ($ Million)

Table 14 South America Hemodynamic Flow Alteration Devices Market Value, By End-User , 2020-2029 ($ Million)

Table 15 South America Hemodynamic Flow Alteration Devices Market Value, By Country, 2020-2029 ($ Million)

Table 16 Europe Hemodynamic Flow Alteration Devices Market Value, By Type, 2020-2029 ($ Million)

Table 17 Europe Hemodynamic Flow Alteration Devices Market Value, By End-User , 2020-2029 ($ Million)

Table 18 Europe Hemodynamic Flow Alteration Devices Market Value, By Country, 2020-2029 ($ Million)

Table 19 Asia-Pacific Hemodynamic Flow Alteration Devices Market Value, By Type, 2020-2029 ($ Million)

Table 20 Asia-Pacific Hemodynamic Flow Alteration Devices Market Value, By End-User , 2020-2029 ($ Million)

Table 21 Asia-Pacific Hemodynamic Flow Alteration Devices Market Value, By Country, 2020-2029 ($ Million)

Table 22 Middle East &amp; Africa Hemodynamic Flow Alteration Devices Market Value, By Type, 2020-2029 ($ Million)

Table 23 Middle East &amp; Africa Hemodynamic Flow Alteration Devices Market Value, By End-User , 2020-2029 ($ Million)

Table 24 Abbott Laboratories: Overview

Table 25 Abbott Laboratories: Product Portfolio

Table 26 Abbott Laboratories: Key Developments

Table 27 Medtronic: Overview

Table 28 Medtronic: Product Portfolio

Table 29 Medtronic: Key Developments

Table 30 Boston Scientific: Overview

Table 31 Boston Scientific: Product Portfolio

Table 32 Boston Scientific: Key Developments

Table 33 Cordis: Overview

Table 34 Cordis: Product Portfolio

Table 35 Cordis: Key Developments

Table 36 Contego Medical: Overview

Table 37 Contego Medical: Product Portfolio

Table 38 Contego Medical: Key Developments

Table 39 Claret Medical: Overview

Table 40 Claret Medical: Product Portfolio

Table 41 Claret Medical: Key Developments

Table 42 BD: Overview

Table 43 BD: Product Portfolio

Table 44 BD: Key Developments

Table 45 Biosensors International Group Ltd: Overview

Table 46 Biosensors International Group Ltd: Product Portfolio

Table 47 Biosensors International Group Ltd: Key Developments

Table 48 Sensome: Overview

Table 49 Sensome: Product Portfolio

Table 50 Sensome: Key Developments

Table 51 Rapid Medical: Overview

Table 52 Rapid Medical: Product Portfolio

Table 53 Rapid Medical: Key Developments

Table 54 Asahi Intec Co.Ltd: Overview

Table 55 Asahi Intec Co.Ltd: Product Portfolio

Table 56 Asahi Intec Co.Ltd: Key Development

Table 57 Stryker Corporation: Overview

Table 58 Stryker Corporation: Product Portfolio

Table 59 Stryker Corporation: Key Development

Table 60 BALT: Overview

Table 61 BALT: Product Portfolio

Table 62 BALT: Key Development

Table 63 Evasc: Overview

Table 64 Evasc: Product Portfolio

Table 65 Evasc: Key Development

Table 66 Kaneka Corp: Overview

Table 67 Kaneka Corp: Product Portfolio

Table 68 Kaneka Corp: Key Development

List of Figures

Figure 01 Global Hemodynamic Flow Alteration Devices Market Share, By Type, 2021 &amp; 2029 (%)

Figure 02 Global Hemodynamic Flow Alteration Devices Market Share, By End-User , 2021 &amp; 2029 (%)

Figure 03 Global Hemodynamic Flow Alteration Devices Market Share, By Region, 2021 &amp; 2029 (%)

Figure 04 Global Hemodynamic Flow Alteration Devices Market Value, 2020-2029 ($ Million)

Figure 05 Global Hemodynamic Flow Alteration Devices Market Y-o-Y Growth, By Type, 2021-2029 (%)

Figure 06 Embolic protection devices: Global Hemodynamic Flow Alteration Devices Market Value, 2020-2029 ($ Million)

Figure 07 Chronic total occlusion devices: Global Hemodynamic Flow Alteration Devices Market Value, 2020-2029 ($ Million)

Figure 08 Global Hemodynamic Flow Alteration Devices Market Y-o-Y Growth, By End-User , 2021-2029 (%)

Figure 09 Hospitals: Global Hemodynamic Flow Alteration Devices Market Value, 2020-2029 ($ Million)

Figure 10 Clinics: Global Hemodynamic Flow Alteration Devices Market Value, 2020-2029 ($ Million)

Figure 11 Ambulatory Care Center: Global Hemodynamic Flow Alteration Devices Market Value, 2020-2029 ($ Million)

Figure 12 Home Care Setting: Global Hemodynamic Flow Alteration Devices Market Value, 2020-2029 ($ Million)

Figure 13 Global Hemodynamic Flow Alteration Devices Market Y-o-Y Growth, By Region, 2021-2029 (%)

Figure 14 North America Hemodynamic Flow Alteration Devices Market Value, 2020-2029 ($ Million)

Figure 15 North America Hemodynamic Flow Alteration Devices Market Share, By Type, 2021 &amp; 2029 (%)

Figure 16 North America Hemodynamic Flow Alteration Devices Market Share, By End-User , 2021 &amp; 2029 (%)

Figure 17 North America Hemodynamic Flow Alteration Devices Market Share, By Country, 2021 &amp; 2029 (%)

Figure 18 South America Hemodynamic Flow Alteration Devices Market Value, 2020-2029 ($ Million)

Figure 19 South America Hemodynamic Flow Alteration Devices Market Share, By Type, 2021 &amp; 2029 (%)

Figure 20 South America Hemodynamic Flow Alteration Devices Market Share, By End-User , 2021 &amp; 2029 (%)

Figure 21 South America Hemodynamic Flow Alteration Devices Market Share, By Country, 2021 &amp; 2029 (%)

Figure 22 Europe Hemodynamic Flow Alteration Devices Market Value, 2020-2029 ($ Million)

Figure 23 Europe Hemodynamic Flow Alteration Devices Market Share, By Type, 2021 &amp; 2029 (%)

Figure 24 Europe Hemodynamic Flow Alteration Devices Market Share, By End-User , 2021 &amp; 2029 (%)

Figure 25 Europe Hemodynamic Flow Alteration Devices Market Share, By Country, 2021 &amp; 2029 (%)

Figure 26 Asia-Pacific Hemodynamic Flow Alteration Devices Market Value, 2020-2029 ($ Million)

Figure 27 Asia-Pacific Hemodynamic Flow Alteration Devices Market Share, By Type, 2021 &amp; 2029 (%)

Figure 28 Asia-Pacific Hemodynamic Flow Alteration Devices Market Share, By End-User , 2021 &amp; 2029 (%)

Figure 29 Asia-Pacific Hemodynamic Flow Alteration Devices Market Share, By Country, 2021 &amp; 2029 (%)

Figure 30 Middle East &amp; Africa Hemodynamic Flow Alteration Devices Market Value, 2020-2029 ($ Million)

Figure 31 Middle East &amp; Africa Hemodynamic Flow Alteration Devices Market Share, By Type, 2021 &amp; 2029 (%)

Figure 32 Middle East &amp; Africa Hemodynamic Flow Alteration Devices Market Share, By End-User , 2021 &amp; 2029 (%)

Figure 33 Abbott Laboratories: Financials

Figure 34 Medtronic: Financials

Figure 35 Boston Scientific: Financials

Figure 36 Cordis: Financials

Figure 37 Contego Medical: Financials

Figure 38 Claret Medical: Financials

Figure 39 BD: Financials

Figure 40 Biosensors International Group Ltd: Financials

Figure 41 Sensome: Financials

Figure 42 Rapid Medical: Financials

Figure 43 Asahi Intec Co.Ltd: Financials

Figure 44 Stryker Corporation: Financials

Figure 45 BALT: Financials

Figure 46 Evasc: Financials

Figure 47 Kaneka Corp: Financials